528 related articles for article (PubMed ID: 25838292)
1. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
2. External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
Kataoka Y; Yamamoto Y; Otsuki T; Kaku S; Maehashi-Wada N; Fukuma S; Hirabayashi M; Nakano T; Fukuhara S
Lung Cancer; 2017 Nov; 113():88-92. PubMed ID: 29110856
[TBL] [Abstract][Full Text] [Related]
3. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
8. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
[TBL] [Abstract][Full Text] [Related]
9. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
10. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
Berardi R; Caramanti M; Fiordoliva I; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Castagnani M; Rovinelli F; Onofri A; Cascinu S
Support Care Cancer; 2015 Mar; 23(3):621-6. PubMed ID: 25142706
[TBL] [Abstract][Full Text] [Related]
11. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
[TBL] [Abstract][Full Text] [Related]
12. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Mutlu H; Buyukcelik A; Karaca H; Aksahin A; Berk V; Aslan T; Erden A; Akca Z; Ozkan M
Asian Pac J Cancer Prev; 2013; 14(6):3887-9. PubMed ID: 23886202
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
14. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for 100 patients with malignant pleural mesothelioma.
Gonlugur U; Gonlugur TE
Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
[TBL] [Abstract][Full Text] [Related]
16. Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
Lau B; Kumar S; Yan T; Burn J; Kennedy C; McLean J; Boyer M; McCaughan B; Kao S
Lung Cancer; 2017 Sep; 111():75-78. PubMed ID: 28838403
[TBL] [Abstract][Full Text] [Related]
17. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
19. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
20. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
